MedTrace Logo

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)

NCT06675422 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-11-05

No results posted yet for this study

Summary

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

DRUG

JY231 injection

Dose escalation was carried out using the 3+3 principle and the mode of administration was intravenous.

Sponsors & Collaborators

  • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

    lead OTHER

Principal Investigators

  • Sanbin Wang, Doctor · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-09
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06675422 on ClinicalTrials.gov